(Epoch Times)

Can HPV Vaccine Prevent Cervical Cancer: Current Studies (Part 3)

In part 1 and part 2 of this series, we discussed the HPV vaccine and its links to ovarian insufficiency and autoimmune disease. In part 3, we turn to questions regarding the effectiveness of the vaccine to prevent cervical cancer, and the limitations of relevant clinical trials to detect such a type of effect.

Summary of Key Facts

• There are multiple obstacles in designing a valid clinical trial to prove the HPV vaccine could prevent cervical cancer, e.g. long lead time, lack of adequate informed consent, complexity between HPV infection and cervical cancer, and the negative impact of girls’ sexual behavior, which may worsen the risks of cervical cancer.
• Most of the HPV’s interventional clinical trials have too short a follow-up time to draw a concrete conclusion.
• In a large Swedish observational trial, which is treated as the most convincing study to prove the HPV vaccine’s effects on cervical cancer, a few confounding factors were not adequately balanced between the HPV vaccination group versus the unvaccinated group.
• The National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data and another U.S. study found the HPV vaccine has no effects in reducing cancer rates.
• Two other registry-based studies in Australia and the UK suggest that HPV vaccination is associated with increased cervical cancer rates in certain age groups.

Long Lead Time from HPV Infection to Cervical Cancer

Typically, there is a long period from HPV infection to cervical epithelium abnormalities, then cervical cancer.

HPV infections usually last 12–18 months and are eventually cleared by the immune system. Fewer than 10 percent of HPV infections are persistent.

There are two types of precancerous cervical lesions, low-grade or high-grade. Low-grade cervical neoplasia grade 1 (CIN1) is usually transient and resolves naturally within one to two years.

Only a few persistent infections progress to the clinically meaningful high-grade, CIN2 or 3. Meanwhile, the median time from CIN2/3 to transition to cancer is estimated to be 23.5 years. Among those with weakened immune systems, HPV-related cancer might progress more quickly.

In a review of the natural history of HPV infection, the complex pathway from infection to cancer is elucidated, including what is known (purple boxes) and where uncertainty remains (blue boxes).

Schematic model of the population-level natural history of HPV infection and cervical cancer. Purple boxes indicate well-accepted natural history model parameters; blue boxes represent uncertainties. (Viruses/MDPI)

Difficulty Running Clinical Trials for the HPV Vaccine

Because of the long lead time from HPV infection to cervical cancer, a prospective, randomized controlled trial is not easily designed and feasibly implemented. Lack of long-term follow-up is a common issue for most clinical trials to prove the HPV vaccine’s effectiveness in preventing cervical cancer.

For example, a 2007 study found that Gardasil was effective in reducing HPV-associated cervical precancerous lesions rate by 20 percent. This study followed their subjects for only an average of 3 years after administration of the first dose.

Furthermore, due to the complex uncertainties in the natural history between HPV infection and cervical cancer, it is not easy to claim the effectiveness of the HPV vaccine. A randomized trial is designed to balance the two groups—vaccine and placebo—so that any unmeasured confounding variables which might influence the outcome of the trial are distributed evenly. However, if the treatment group knows they got the vaccine, might their behaviors change? Might they be less risk-averse, thinking they have some protection?

For example, girls might think they are vaccinated and “protected” from cervical cancer and may tend to initiate sexual intercourse at a younger age or engage in sexual activities with more partners. However, sexual intercourse at a young age, multiple sexual partners, and oral contraceptive use are associated with an increased risk of cervical cancer in women.

In other words, HPV vaccination may offer some protection if offered before sexual activity is initiated, but it may also be associated with increased behavioral risk factors. Whether the benefits of vaccination outweigh any risks is therefore a multifactorial question deserving of careful longitudinal study.

Systemic Analysis of 12 Clinical Trials on HPV Vaccine Efficacy

In 2020, a Queen Mary University study led by Dr. Claire Rees reviewed 12 randomized clinical trials for Cervarix and Gardasil. The investigators found that the trials did not include populations representative of the vaccination target groups, and the trial design may have overstated vaccine efficacy.

For example, one trial design generated evidence that the vaccine prevents CIN1. But this is not meaningful because these lesions usually resolve on their own.

Furthermore, the study accessed efficacy against low-grade precancerous lesions. But this is not necessarily suggestive of efficacy against the more serious but much less frequent high-grade lesions.

Finally, the cytology screenings were done every six to 12 months instead of every 36 months (normal screening interval), meaning the efficacy of the vaccine may have been overestimated, as low-grade lesions could go away spontaneously.

All this is to say the HPV vaccine may be effective at preventing more serious lesions which lead to cervical cancer, but it is hard to know because of these poorly designed trials. Nothing is conclusive without a larger trial powered to detect a difference in rates of more serious cervical changes according to the typical screening schedule. However, such a trial has not yet been performed.

Swedish Nationwide Health Registry Study

A nationwide Swedish health registry-based study followed 1,672,983 women for 12 years to assess the association between HPV vaccination and the risk of cervical cancer.

In this study, the cumulative incidence of cervical cancer was 47 cases per 100,000 women vaccinated and 94 per 100,000 unvaccinated, suggesting that HPV4 vaccination was associated with a reduced risk of 49 to 63 percent of invasive cervical cancer at the population level.

Even though the results are positive, the study researchers raised a few concerns themselves.

First, HPV-vaccinated women could have been generally healthier than unvaccinated women. This is known as “healthy volunteer bias.”

Second, a mother’s history of cervical cancer might be associated with both vaccination uptake and underlying risk of cervical cancer as well as screening rates.

Third, lifestyle and health factors such as smoking, sexual intercourse at a young age, multiple sexual partners, oral contraceptive use, and obesity are reportedly associated with the risk of cervical cancer. These factors have not been thoroughly analyzed by this study and could have contributed to the data.

Furthermore, parental education level and annual household income level may be interconnected with lifestyle factors such as smoking status.

Strengths of this study include its size, duration, and outcome of interest being invasive cancer, not low-grade lesions. However, it is impossible to exclude the relationship between lifestyle factors, vaccination uptake, and cervical cancer. Only a randomized controlled trial (RCT) could balance the two groups on these unmeasured—but related—risk factors. However even if the risk factors (sexual behaviors) are fully balanced at baseline with an RCT, it is hard to keep them still balanced during the whole study course after HPV vaccination.

No Association Found in a US Database

Meanwhile, researchers found no association between vaccination and cancer mortality in the United States.

According to the National Cancer Institute’s SEER program, the incidence of deaths from cervical cancer before Gardasil’s introduction in the United States had been steadily declining for years and, in 2006, was 2.4 per 100,000 women. The data from 2016–2020 is 2.2 per 100,000 women—essentially unchanged.

In a cross-sectional study using a nationally representative sample of United States adults aged 20–59 years, among 9,891 participants, the researchers did not find an association between HPV vaccination and HPV-related cancers.

Increase in Cervical Cancer After HPV Vaccine Rollout: Australia

In Australia, government data similarly reveal an increase in cervical cancer rates in certain age groups of women following the implementation of the Gardasil vaccine.

Thirteen years after Gardasil was recommended for teenagers and young adults, there has been a 30 percent increase in 30- to 34-year-old women (4.9 cases/100,000 compared to 6.6 cases/100,000 in 2020) being diagnosed with cervical cancer.

Even though the rates decreased in other age groups, the abnormal increase in the 30–34 age group needs an explanation.